← Back to Search

Monoclonal Antibodies

XmAb®22841 for Solid Tumors(DUET-4 Trial)

Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, MI
Targeting 24 different conditionsXmAb®22841 +1 morePhase 1Waitlist AvailableResearch Sponsored by Xencor, Inc.

DUET-4 Trial Summary

This trial is testing a new drug, XmAb22841, to see if it is safe and works well against cancer when given alone or with another drug, pembrolizumab.

Eligible Conditions
  • Advanced or Metastatic Solid Tumors
  • Squamous Cell Carcinoma
  • Nasopharyngeal Cancer
  • Kidney Cancer
  • Non-Small Cell Lung Cancer
  • Breast Cancer
  • Vulvar Squamous Cell Carcinoma
  • Melanoma
  • Ovarian Cancer
  • Cervical Cancer
  • Anal Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Liver Cancer
  • Bladder Cancer
  • Peritoneal Carcinoma
  • Endometrial Cancer
  • Gastric Cancer
  • Intrahepatic Cholangiocarcinoma
  • Penile Cancer
  • Small Cell Lung Cancer
  • Prostate Cancer

DUET-4 Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have a type of advanced cancer that has either not responded to other treatments, or you cannot tolerate the standard treatment, or you have not received a type of medication that targets PD1 or PDL1.
You have a confirmed advanced or metastatic solid tumor that has not responded to all available treatments that are known to help, or you cannot tolerate treatment, or you do not want to have standard treatment. You have one of these eligible types of tumors: melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, gastric adenocarcinoma, cervical carcinoma, triple-negative breast carcinoma, epithelial ovarian cancer, nasopharyngeal carcinoma, squamous cell anal carcinoma, squamous cell penile carcinoma, or squamous cell vulvar carcinoma.
You have been diagnosed with advanced or metastatic cancer in one of the following areas: skin, cervix, pancreas, breast, liver, bladder, head and neck, nasopharynx, kidney, colon, uterus, lung, stomach, prostate, or ovaries.

DUET-4 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~56 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 56 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

DUET-4 Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm 2Experimental Treatment2 Interventions
Arm 2: Combination of XmAb®22841 and Pembrolizumab (Keytruda®)
Group II: Arm 1Experimental Treatment1 Intervention
Arm 1: XmAb®22841 Monotherapy
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1
Pembrolizumab (Keytruda®)
Completed Phase 1

Find a Location

Who is running the clinical trial?

Xencor, Inc.Lead Sponsor
27 Previous Clinical Trials
2,375 Total Patients Enrolled
ICON Clinical ResearchIndustry Sponsor
49 Previous Clinical Trials
15,273 Total Patients Enrolled
Benjamin Thompson, MD, PhDStudy DirectorXencor, Inc.
1 Previous Clinical Trials
4 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What therapeutic applications is XmAb®22841 regularly employed for?

"XmAb®22841 is a promising therapeutic for treating malignant neoplasms. It can also be used to combat unresectable melanoma, microsatellite instability high conditions, and disease progression after chemotherapy."

Answered by AI

Is this experiment currently enrolling participants?

"Based on the clinicaltrials.gov listing, this research project is not currently looking for individuals to participate in their trial. The study was initially listed in May 2019 and last edited two days ago in late May 2022; however, there are 9205 other trials actively seeking participants as of now."

Answered by AI

Are there any records of precedent studies involving XmAb®22841?

"Currently, 963 different trials are underway to investigate the effects of XmAb®22841. Out of these studies, 122 have progressed to Phase 3. The majority of clinical investigations for this treatment occur in Houston, Texas; however many other sites across 35772 locations have also been enlisted as trial centres."

Answered by AI

To what degree is XmAb®22841 a risk for individuals?

"Research into the safety of XmAb®22841 is still in its infancy. Our team at Power estimates that this drug's security rating is a 1 out of 3 due to limited data supporting efficacy and safety."

Answered by AI

To what extent is this experiment being administered to participants?

"Unfortunately, this investigation is no longer enlisting participants. It was initially advertised on May 29th 2019 and the most recent update to its listing occurred on May 27th 2022. If you are looking for other possibilities, there are 8242 clinical trials recruiting individuals with melanoma and 963 studies actively enrolling people in XmAb®22841 experiments."

Answered by AI

How many test sites are conducting this experiment?

"This research is currently engaging with 28 different medical centres, such as UCSD Altman Clinical and Translational Research Institute Building (ACTRI) in La Jolla, UCSD Perlman Medical Offices in Los Angeles, and UC San Diego Moores Cancer Center in San Diego. Additionally, there are numerous other enrolment sites."

Answered by AI
~14 spots leftby Nov 2024